Duvelisib/Romidepsin for Patients With Relapsed/Refractory Peripheral T-Cell Lymphoma: Steven M. Horwitz, MD

For patients with relapsed/refractory T-cell lymphoma (TCL), standard therapies provide an overall response rate of only 25% to 35%, and novel therapeutic options are greatly needed. In a study recently presented at the American Society of Hematology (ASH) 63rd Annual Meeting & Exposition in Atlanta, Georgia, a team of researchers led by Dr. Steven M. Horwitz, medical oncologist at Memorial Sloan Kettering Cancer Center, investigated the efficacy of the phosphoinositide-3-kinase inhibitor du...

Continue reading

Recent Advances in T-Cell Lymphoma: A Conversation with Dr. Steven Horwitz

·

In this podcast, Dr. Steven Horwitz of  Memorial Sloan Kettering Cancer Center discusses recent progress in the treatment and management of T-cell lymphoma. Listen now to hear more!

Continue reading

Subscribe

Get the latest updates delivered to your inbox!

Follow Us

Copyright © 2022 Oncology Data Advisor. All rights reserved.